NFL BIOSCIENCES EO -03
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding… Read more
Market Cap & Net Worth: NFL BIOSCIENCES EO -03 (82F)
NFL BIOSCIENCES EO -03 (F:82F) has a market capitalization of $13.06 Million (€12.72 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #29323 globally and #3231 in its home market, demonstrating a 3.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NFL BIOSCIENCES EO -03's stock price €1.00 by its total outstanding shares 12672242 (12.67 Million).
NFL BIOSCIENCES EO -03 Market Cap History: 2021 to 2026
NFL BIOSCIENCES EO -03's market capitalization history from 2021 to 2026. Data shows change from $31.87 Million to $13.06 Million (-21.96% CAGR).
NFL BIOSCIENCES EO -03 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NFL BIOSCIENCES EO -03's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 82F by Market Capitalization
Companies near NFL BIOSCIENCES EO -03 in the global market cap rankings as of March 19, 2026.
Key companies related to NFL BIOSCIENCES EO -03 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
NFL BIOSCIENCES EO -03 Historical Marketcap From 2021 to 2026
Between 2021 and today, NFL BIOSCIENCES EO -03's market cap moved from $31.87 Million to $ 13.06 Million, with a yearly change of -21.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €13.06 Million | -7.21% |
| 2025 | €14.07 Million | -38.52% |
| 2024 | €22.89 Million | +34.97% |
| 2023 | €16.96 Million | -34.80% |
| 2022 | €26.02 Million | -18.37% |
| 2021 | €31.87 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of NFL BIOSCIENCES EO -03 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.06 Million USD |
| MoneyControl | $13.06 Million USD |
| MarketWatch | $13.06 Million USD |
| marketcap.company | $13.06 Million USD |
| Reuters | $13.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.